ScripLeading South Korean antibody-drug conjugate (ADC) specialist LigaChem Biosciences has made a $25m investment for an initial 26.6% equity stake in existing partner IKSUDA Therapeutics, and secured the
ScripMergers and acquisitions usually happen in major global biopharma markets as a way to gain new technologies, R&D or commercial portfolios, expand a business or to beef up supply networks. But in S
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C
ScripSentiment around initial public offerings (IPOs) appears to be slowly recovering in South Korea as the market stabilizes somewhat amid ongoing political uncertainties at home and abroad. A couple of b